|
Name |
Isopinocarveol
|
Molecular Formula | C10H16O | |
IUPAC Name* |
(1R,3R,5R)-6,6-dimethyl-2-methylidenebicyclo[3.1.1]heptan-3-ol
|
|
SMILES |
CC1([C@@H]2C[C@H]1C(=C)[C@@H](C2)O)C
|
|
InChI |
InChI=1S/C10H16O/c1-6-8-4-7(5-9(6)11)10(8,2)3/h7-9,11H,1,4-5H2,2-3H3/t7-,8+,9-/m1/s1
|
|
InChIKey |
LCYXQUJDODZYIJ-HRDYMLBCSA-N
|
|
Synonyms |
Pinocarveol, cis-(+/-)-; Isopinocarveol; cis-Pinocarveol; trans-Pinocarveol; 2(10)-Pinen-3-ol, cis-; 6712-79-4; 31P964S048; Bicyclo(3.1.1)heptan-3-ol, 6,6-dimethyl-2-methylene-, (1R,3R,5R)-rel-; 1674-08-4; UNII-31P964S048; cis-(+/-)-pinocarveol; DTXSID00217419; BICYCLO(3.1.1)HEPTAN-3-OL, 6,6-DIMETHYL-2-METHYLENE-, (1.ALPHA.,3.BETA.,5.ALPHA.)-; ZINC4102279; Bicyclo(3.1.1)heptan-3-ol, 6,6-dimethyl-2-methylene-, (1alpha,3beta,5alpha)-; Q27256073; (1R,5beta)-6,6-Dimethyl-2-methylenebicyclo[3.1.1]heptan-3alpha-ol; Bicyclo[3.1.1]heptan-3-ol,6,6-dimethyl-2-methylene-,(1R,3S,5R)-rel-; BICYCLO[3.1.1]HEPTAN-3-OL,6,6-DIMETHYL-2-METHYLENE-, (1R,3S,5R)-REL-
|
|
CAS | 3917-59-7 | |
PubChem CID | 10931630 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 152.23 | ALogp: | 1.8 |
HBD: | 1 | HBA: | 1 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 20.2 | Aromatic Rings: | 3 |
Heavy Atoms: | 11 | QED Weighted: | 0.529 |
Caco-2 Permeability: | -4.55 | MDCK Permeability: | 0.00002420 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.102 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.183 |
30% Bioavailability (F30%): | 0.015 |
Blood-Brain-Barrier Penetration (BBB): | 0.12 | Plasma Protein Binding (PPB): | 63.34% |
Volume Distribution (VD): | 1.385 | Fu: | 41.54% |
CYP1A2-inhibitor: | 0.269 | CYP1A2-substrate: | 0.102 |
CYP2C19-inhibitor: | 0.034 | CYP2C19-substrate: | 0.773 |
CYP2C9-inhibitor: | 0.095 | CYP2C9-substrate: | 0.446 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.391 |
CYP3A4-inhibitor: | 0.015 | CYP3A4-substrate: | 0.252 |
Clearance (CL): | 7.364 | Half-life (T1/2): | 0.351 |
hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.172 |
Drug-inuced Liver Injury (DILI): | 0.112 | AMES Toxicity: | 0.003 |
Rat Oral Acute Toxicity: | 0.571 | Maximum Recommended Daily Dose: | 0.965 |
Skin Sensitization: | 0.246 | Carcinogencity: | 0.047 |
Eye Corrosion: | 0.97 | Eye Irritation: | 0.994 |
Respiratory Toxicity: | 0.956 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000482 | 0.474 | D0V8HA | 0.220 | ||||
ENC000613 | 0.400 | D0H1QY | 0.208 | ||||
ENC000153 | 0.400 | D04CSZ | 0.208 | ||||
ENC000790 | 0.341 | D04VIS | 0.198 | ||||
ENC000151 | 0.333 | D04DJN | 0.189 | ||||
ENC003096 | 0.333 | D0G5CF | 0.181 | ||||
ENC005520 | 0.318 | D08SVH | 0.181 | ||||
ENC002228 | 0.311 | D0T2PL | 0.181 | ||||
ENC000830 | 0.296 | D05BTM | 0.181 | ||||
ENC002902 | 0.292 | D0A2AJ | 0.179 |